| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
During the period of this grant, we revealed many new findings about the usefulness of the combined cocktail therapy with hepatic progenitor cells (HPC) and clinical available agents such as angiotensin II receptor blocker (ARB) in several types of animal models of liver fibrosis development and hepatocarcinogenesis. Even at clinical comparable low doses of these agents, we observed significant inhibitory effects on the liver fibrosis development, hepatocarcinogenesis, and the growth of hepatocellular carcinoma (HCC) with many publications in international journals. Furthermore, we observed that specific NOTCH-1 inhibitor significantly suppressed the liver fibrosis development along with augmentation of hepatic regeneration. It is well known that augmentation of liver regeneration would play a pivotal role for improvement of hepatic reserve. Collectively, our studies with this grant could contribute to the improvement of prognosis in patients with chronic liver diseases.
|
